We next used the VEGFA inhibitor bevacizumab30, with no additional VEGF (as the AML cells express it already), and the IL5RA inhibitor benralizumab31 with or without exogenous IL-5, to test whether the inhibitors would abrogate growth stimulation. This evidence concerns the gene IL5 and acute myeloid leukemia.